Video
Dr. Alexander Kretschmer on next steps for ExoDx Prostate test
Author(s):
Video Player is loading.
Dr. Alexander Kretschmer, MD, discusses the next steps with research and clinical use of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result
Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.
Related Videos
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
Using Ultrasensitive PSA Assays in Routine Practice
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
Study findings highlight gender gaps in oncology authorship and citation
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jim Hu, MD, on urinary continence recovery across RARP techniques
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Special Report: Tips for PCPs on evaluating prostate cancer risk
Related Content
